| DAY ONE: Tuesday February 5 2008 |
| 08.30 |
|
Registration |
| 09.00 |
Mark Horn
Director of Finance and R&D Portfolio Management
Wyeth Consumer Healthcare |
Opening remarks from the Chair |
THE ROLE OF PORTFOLIO MANAGEMENT IN DECISION MAKING |
09:10 |
Markus Thunecke
Senior Partner
CATENION
|
Decision analysis revisited – the unmet needs of portfolio management in 2008 and how to address them
- Decision analysis and portfolio management in pharma – where do we stand?
- Designing a process that really works – from innovation to value
- Building the ideal portfolio - some thoughts from financial theory
- Assessing the impact of quality, size and diversity on the portfolio risk/return and profile
- Organisational prerequisites for successful portfolio management
|
09:50 |
Pasi Piitulainen
Director
Global Clinical Development Affairs ACTELION |
Portfolio management - does it have something to say in corporate decision making?
- The role of portfolio management in light of company strategy.
- What can portfolio management offer to justify its existence?
- Tools to ensure accurate and transparent information flow from the field to the board room
|
| 10:30 |
|
Morning refreshments |
SUCCEEDING IN A VOLATILE INDUSTRY THROUGH EFFECTIVE PORTFOLIO MANAGEMENT |
11:00 |
Roger Holdsworth Associated Director Portfolio Analysis
UCB |
Portfolio analysis throughout the development lifecycle
- Why we need to make informed decisions
- The need for consistent input data
- Appropriate techniques for different stages of the development cycle
- Getting the message across - communication to senior management
|
| 11:40 |
Allan Wehnert
Vice President Corporate Project Management R&D
H.LUNDBECK |
Incorporating portfolio management behaviour into your development process
- Ensure that everyday development programme decisions are aligned with your corporate portfolio strategy
- Empower the development teams and sub-governance committees
- Monitor and re-align progress and critical path activities with the corporate portfolio strategy during the development process
- Assess the value of a yearly portfolio process versus continuously integrated portfolio behaviour
|
| 12:20 |
|
Lunch |
13:40 |
Eric Rambeaux
Vice President
Business Strategy
and Portfolio
SOLVAY |
Analysing the role of marketing in R&D
- Assessing the importance of aligning marketing and R&D for value creation
- Looking at the interface between marketing and R&D in project and portfolio management
- Investigating potential pitfalls and key strategies for success
|
| EVALUATING RISK MANAGEMENT STRATEGIES |
14:20 |
Bernd Seilheimer
Head
Global R&D Risk Management
BAYER SCHERING PHARMA AG |
Integrated risk management in R&D – benefits and challenges
- The difference between Integrated Risk Management and Safety Risk Management
- Benefits beyond business protection
- Key methods and tools
- A typical business case - lessons learned during implementation
|
| 15:00 |
|
Afternoon refreshments |
15:30 |
Kerstin M. Bode-Greuel Associate Lecturer
UNIVERSITY OF ESSEN |
Enhancing pharmaceutical R&D productivity through improved interface management
- Potential issues of R&D interface management that may impair R&D productivity
- Tools for aligning project and portfolio management across R&D interfaces
- Creating a common understanding of project and portfolio risk structure
- Enhancing R&D productivity through cross-functional risk management
|
| 16:10 |
Rafaat Rahmani
Founder and President LIFESCIENCE DYNAMICS |
Valuation and portfolio management
- How to compare and trade-off like for like
- Using financial analysis as a link between strategy and operations
- Uncertainty modelling – identifying and minimizing technical and commercial risks
- Valuation techniques - DCF, ROV & MV
- Optimisation & trade-off
|
| 16:50 |
Manuel Carmona European Sales Manager PALISADE-EUROPE UK Ltd |
Building financial models with @RISK 5.0
- Introduction to a new @RISK 5.0 application - all-new @RISK 5.0 for Excel has been redesigned from the ground up to provide unprecedented model sharing, a revamped interface, and more robust Monte Carlo analyses
- Analyzing risk and uncertainty by using @RISK 5.0 – providing industry specific examples
- The specifics of the application and benefits to pharmaceutical industry
|
17:30 |
|
Closing remarks from the Chair |
| 17:40 |
|
End of day one |
| |
|
|
| |
|
|
DAY TWO: Wednesday February 6 2008 |
| 08:30 |
|
Registration and coffee |
| 09:00 |
Mark Horn
Director of Finance and R&D Portfolio Management
Wyeth Consumer Healthcare |
Opening remarks from the Chair |
13:30 |
Roundtable morning |
Delegates will be able to attend three one-hour roundtable discussion groups from a selection of key topics. Each session will be chaired by an industry expert who will facilitate an exchange of opinions, essential experiences and learning related to an aspect of portfolio management. |
Markus Thunecke
Senior Partner
CATENION |
1. Establishing accurate portfolio worth |
Mark Horn
Director of Finance and R&D Portfolio Management
Wyeth Consumer Healthcare |
2. Lowering costs to increase project portfolio ROI |
Bernd Seilheimer
Head
Global R&D Risk Management
BAYER SCHERING PHARMA AG |
3. Analysing risk management strategies to minimise the impact of market uncertainty |
Roger Holdsworth Associated Director
Portfolio Analysis
UCB |
4. Discussing valuation of a product throughout the development lifecycle
|
| |
Pasi Piitulainen
Director
Global Clinical Development Affairs
ACTELION |
5. Effectively presenting portfolio management to key decision makers
|
12:30 |
|
Lunch |
PORTFOLIO ADVANCEMENT THROUGH BIOTECH/PHARMA COLLABORATION |
13:40 |
David Rosen
Development and Commercial Head Strategic Alliances
PFIZER |
What is the value of in-licensing and alliances in the pharma industry and how are deals evolving for pharma and biotech?
- What creative examples are there of deal-making and relationship management?
- How do you assess value at preclinical stage?
- What are the tensions between pharma and biotech in business deals and how are they being managed?
- What is the partnering wave likely to do to deals and prices in the long term?
|
14:20 |
Andre Hoekema
Senior Vice President Corporate Development GALAPAGOS |
Strategic biotech-pharma alliances - effective portfolio management
- Risk/reward sharing between pharma and biotech - the way forward?
- Galapagos in drug discovery deals with pharma - two case studies
- Demonstrating the advantages from two widely differing perspectives
|
| 15:00 |
|
Afternoon refreshments |
| MAXIMISING PORTFOLIO MANAGEMENT STRATEGIES |
15:20 |
Tony Ellery
Global Head
Project Management General Medicine Specialities and Mature Product Business Franchise
NOVARTIS PHARMA |
Lifecycle management of ethical pharmaceuticals - an evolving challenge?
- What constitutes good LCM?
- What strategies have proved effective in the past?
- What will still be effective in the future
|
| 16:00 |
Kimber Hardy
Senior Director
Portfolio Management
MERCK SERONO |
Closing remarks from the Chair and end of conference
- Link to company strategy
- Risk/reward profiles and strategies
- Setting goals and monitoring
- Optimising portfolio selection
|
| 16:40 |
|
Closing remarks from the Chair |
| 16:50 |
|
End of conference and farewell tea and coffee |
Programme
